Pathway analysis comparing PL4–5 against PL1–3 in tumor samples indicated upregulation of cytokine and interleukin signaling and downregulation of CD22-mediated B-cell receptor (BCR) regulation in PL4–5 (Supplementary Table S9). The gene discussed is CD22; the disease is neoplasm.